| Primary |
| Product Used For Unknown Indication |
16.4% |
| Drug Use For Unknown Indication |
16.1% |
| Sepsis |
7.7% |
| Staphylococcal Infection |
6.1% |
| Infection |
5.8% |
| Osteomyelitis |
5.5% |
| Cellulitis |
4.5% |
| Antibiotic Therapy |
4.2% |
| Pneumonia |
3.9% |
| Clostridial Infection |
3.5% |
| Anti-infective Therapy |
3.2% |
| Endocarditis |
3.2% |
| Febrile Neutropenia |
3.2% |
| Pneumonia Staphylococcal |
3.2% |
| Pyrexia |
3.2% |
| Bacterial Infection |
2.6% |
| Prophylaxis |
2.6% |
| Antibiotic Prophylaxis |
1.9% |
| Immunosuppression |
1.6% |
| Meningitis Bacterial |
1.6% |
|
| Renal Failure Acute |
25.2% |
| Renal Failure |
12.6% |
| Linear Iga Disease |
7.7% |
| Rash |
5.6% |
| Red Man Syndrome |
5.6% |
| Anaphylactic Reaction |
4.2% |
| Hearing Impaired |
3.5% |
| Renal Tubular Disorder |
3.5% |
| Renal Tubular Necrosis |
3.5% |
| Sepsis |
3.5% |
| Gastrointestinal Haemorrhage |
2.8% |
| Medication Error |
2.8% |
| Nephropathy Toxic |
2.8% |
| Pyrexia |
2.8% |
| Respiratory Arrest |
2.8% |
| Urticaria |
2.8% |
| Drug Eruption |
2.1% |
| Neutropenia |
2.1% |
| Pruritus |
2.1% |
| Renal Impairment |
2.1% |
|
| Secondary |
| Product Used For Unknown Indication |
19.4% |
| Drug Use For Unknown Indication |
16.7% |
| Pneumonia |
9.6% |
| Staphylococcal Infection |
5.5% |
| Sepsis |
5.1% |
| Infection |
4.2% |
| Sedation |
3.8% |
| Prophylaxis |
3.8% |
| Osteomyelitis |
3.4% |
| Staphylococcal Abscess |
3.3% |
| Hypertension |
3.2% |
| Febrile Neutropenia |
3.0% |
| Pyothorax |
2.8% |
| Device Related Infection |
2.6% |
| Meningitis |
2.6% |
| Psoas Abscess |
2.4% |
| Fungal Infection |
2.3% |
| Bronchopulmonary Aspergillosis |
2.2% |
| Infection Prophylaxis |
2.0% |
| Prophylaxis Against Diarrhoea |
2.0% |
|
| Toxic Epidermal Necrolysis |
18.6% |
| Tubulointerstitial Nephritis |
8.5% |
| Renal Failure Acute |
8.1% |
| Sepsis |
6.9% |
| Nephropathy Toxic |
6.1% |
| White Blood Cell Count Decreased |
5.7% |
| Renal Disorder |
4.9% |
| Renal Impairment |
4.9% |
| Vertigo |
4.9% |
| Drug Eruption |
3.6% |
| Pyrexia |
3.2% |
| Thrombocytopenia |
3.2% |
| Urinary Retention |
3.2% |
| Multiple-drug Resistance |
2.8% |
| Platelet Count Decreased |
2.8% |
| Stevens-johnson Syndrome |
2.8% |
| Blood Creatinine Increased |
2.4% |
| Interstitial Lung Disease |
2.4% |
| Liver Disorder |
2.4% |
| Pneumonia |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
24.7% |
| Product Used For Unknown Indication |
16.6% |
| Prophylaxis |
11.3% |
| Infection Prophylaxis |
10.9% |
| Bone Marrow Conditioning Regimen |
5.3% |
| Prophylaxis Against Graft Versus Host Disease |
4.2% |
| Pneumonia |
4.1% |
| Premedication |
2.6% |
| Acute Lymphocytic Leukaemia |
2.6% |
| Hypertension |
2.3% |
| Acute Myeloid Leukaemia |
2.3% |
| Aplastic Anaemia |
2.0% |
| Febrile Neutropenia |
1.7% |
| Constipation |
1.5% |
| Antifungal Prophylaxis |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Infection |
1.3% |
| Sepsis |
1.3% |
| Pain |
1.2% |
|
| Pyrexia |
12.6% |
| Vomiting |
12.1% |
| White Blood Cell Count Decreased |
10.9% |
| Renal Impairment |
6.8% |
| Sepsis |
6.0% |
| Thrombocytopenia |
5.6% |
| Pneumonia |
5.3% |
| Septic Shock |
4.3% |
| Respiratory Failure |
4.1% |
| Death |
3.9% |
| Venoocclusive Liver Disease |
3.9% |
| Pseudomembranous Colitis |
3.4% |
| Renal Failure Acute |
3.1% |
| Pancytopenia |
2.9% |
| Platelet Count Decreased |
2.7% |
| Renal Failure |
2.7% |
| Urinary Tract Infection |
2.7% |
| Hypokalaemia |
2.4% |
| Neutrophil Count Decreased |
2.4% |
| Rash |
2.4% |
|
| Interacting |
| Endocarditis Bacterial |
50.0% |
| Blood Pressure Increased |
25.0% |
| Weight Increased |
25.0% |
|
| International Normalised Ratio Increased |
50.0% |
| Renal Impairment |
50.0% |
|
